Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIN001
- Development stage
- Phase 2
- Lead developer
- Curatis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KIN001 is an orally available combination therapy comprising pamapimod, a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), and pioglitazone, an agonist of the peroxisome proliferator-activated receptor gamma (PPARγ). Developed by Kinarus Therapeutics (acquired by Curatis), the combination is designed to provide synergistic anti-inflammatory and anti-fibrotic effects. Pamapimod inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6, while pioglitazone modulates gene expression involved in glucose and lipid metabolism as well as inflammation. KIN001 has been investigated in Phase 2 clinical trials for the treatment of COVID-19 (KINFAST and KINETIC studies) and is being developed for idiopathic pulmonary fibrosis (IPF) and other orphan fibrotic diseases.
- Other names
- pamapimod + pioglitazone
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)MAPK14 (p38 mitogen-activated protein kinase alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on KIN001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIN001.